Novartis weighs bid for Takeda eye-disease assets

Bloomberg reports  Novartis (NVS) is weighing a bid for the eye-disease assets that Takeda (TKPYY) acquired through its $62B takeover of Shire (SHPG), Bloomberg’s Manuel Baigorri, James Paton, and Dinesh Nair report, citing people familiar with the situation. Novartis is among companies eyeing the business, which includes Xiidra prescription drops, the authors say. No final decision has been made and the Swiss drugmaker could choose to pursue different targets or Takeda could select a different buyer for the assets, the authors note.

https://thefly.com/landingPageNews.php?id=2905927